U.S. markets close in 2 hours 40 minutes
  • S&P 500

    4,355.55
    -87.56 (-1.97%)
     
  • Dow 30

    34,324.63
    -544.74 (-1.56%)
     
  • Nasdaq

    14,564.53
    -405.44 (-2.71%)
     
  • Russell 2000

    2,237.52
    -43.49 (-1.91%)
     
  • Crude Oil

    75.01
    -0.44 (-0.58%)
     
  • Gold

    1,736.40
    -15.60 (-0.89%)
     
  • Silver

    22.46
    -0.20 (-0.87%)
     
  • EUR/USD

    1.1686
    -0.0015 (-0.13%)
     
  • 10-Yr Bond

    1.5310
    +0.0470 (+3.17%)
     
  • GBP/USD

    1.3535
    -0.0169 (-1.23%)
     
  • USD/JPY

    111.4830
    +0.5050 (+0.46%)
     
  • BTC-USD

    41,218.65
    -1,986.72 (-4.60%)
     
  • CMC Crypto 200

    1,015.65
    -41.49 (-3.93%)
     
  • FTSE 100

    7,028.10
    -35.30 (-0.50%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Endo International plc ENDP beats on both earnings and sales in the fourth quarter, driven by growth in its Branded Pharmaceuticals segment.

The company’s earnings of 75 cents easily beat the Zacks Consensus Estimate of 50 cents in the reported quarter but decreased from 80 cents in the year-ago quarter.

Endo International plc Price, Consensus and EPS Surprise

Endo International plc Price, Consensus and EPS Surprise
Endo International plc Price, Consensus and EPS Surprise

Endo International plc price-consensus-eps-surprise-chart | Endo International plc Quote

Revenues came in at $760 million in the fourth quarter, surpassing the Zacks Consensus Estimate of $654 million but was down 1% from the year-ago quarter. The decline was attributed to lower Generic Pharmaceuticals segment’s revenues.

Quarterly Highlights

Endo has four reportable business segments — Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables and International Pharmaceuticals.

Branded Pharmaceuticals revenues were $224.5 million compared to $225.5 million in the year-ago quarter. Within the segment, Specialty Products revenues increased 4% to $154 million. Sales of Xiaflex increased 4% to $105 million. However, Established Products revenues decreased 8% to $71 million.

Sterile Injectables revenues came in at $332 million, up 16% year over year primarily driven by higher Vasostrict revenues.

Generic Pharmaceuticals reported sales of $180 million in the quarter, down 20% due to continued competitive pressures on certain key products.

International Pharmaceuticals revenues came in at $23 million, down 18% year over year.

2020 Results

Revenues in 2020 came in at $2.9 billion, declining slightly from $2.91 billion in 2019 but easily beating the Zacks Consensus Estimate of $2.80 billion.

Earnings per share of $2.87 grew from $2.66 in 2019 and easily beat the Zacks Consensus Estimate of $2.60 per share.

2021 Guidance

Endo expects revenues of $620-$680 million and earnings per share of $0.40-$0.50 in the first quarter. Revenues for 2021 are projected to be $2.55-$2.79 billion. Adjusted earnings per share are now estimated to be $1.80-$2.30.

Our Take

Endo reported better-than-expected results for the fourth quarter as the Branded Pharmaceuticals segment continues to maintain momentum.

Shares of Endo have gained 29.6% in the year so far against the industry’s 1.7% growth.

The company’s efforts to revive its business are encouraging. The acquisition of BioSpecifics Technologies Corp. will fuel growth. Last year, the FDA approved QWO (collagenase clostridium histolyticum-aaes) for the treatment of moderate-to-severe cellulite in the buttocks of adult women (anticipated launch in spring). This should strengthen the company’s portfolio.

Earlier, Endo also announced a fill-finish manufacturing and services agreement for Novavax's NVAX COVID-19 vaccine candidate, NVX-CoV2373.
Its efforts to optimize operations and increase overall efficiency should aid the bottom line as well.

Zacks Rank & Stocks to Consider

Endo currently carries a Zacks Rank # 3 (Hold).

A couple of better-ranked stocks in the healthcare space are Repligen RGEN and Dynavax Technologies Corporation DVAX, both carrying a Zacks Rank #2 (Buy), presently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Repligen’s earnings per share estimates have moved up from $1.63 to $1.72 for 2021 in the past 90 days.

Dynavax loss per share estimates for 2021 have narrowed to 17 cents from 45 cents in the past 30 days.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.9% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Endo International plc (ENDP) : Free Stock Analysis Report

Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research